CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS/TOP PLAYER POSITIONING, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS

3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities

CHAPTER 4 GLOBAL CLARITYNE MARKET, BY PRODUCT

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. LORATADINE TABLET

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. LORATADINE CAPSULES

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. LORATADINE SYRUP

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

CHAPTER 5 GLOBAL CLARITYNE MARKET, BY END USER

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. ADULTS

5.2.1. Market size and forecast 

5.3. PEDIATRICS

5.3.1. Market size and forecast

CHAPTER 6 GLOBAL CLARITYNE MARKET, BY REGION

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast

6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast

6.2.4. North America Clarityne Market by Product
6.2.5. North America Clarityne Market by End User

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast

6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Spain market size and forecast
6.3.3.6. Rest of Europe market size and forecast

6.3.4. Europe Clarityne Market by Product
6.3.5. Europe Clarityne Market by End User

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast

6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. Australia market size and forecast
6.4.3.4. India market size and forecast
6.4.3.5. Rest of Asia-Pacific market size and forecast

6.4.4. Asia-Pacific Clarityne Market by Product
6.4.5. Asia-Pacific Clarityne Market by End User

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast

6.5.3.1. Brazil market size and forecast
6.5.3.2. Argentina market size and forecast
6.5.3.3. Saudi Arabia market size and forecast
6.5.3.4. South Africa market size and forecast
6.5.3.5. Rest of LAMEA market size and forecast

6.5.4. LAMEA Clarityne Market by Product
6.5.5. LAMEA Clarityne Market by End User

CHAPTER 6 COMPANY PROFILES

6.1. MERCK AND CO. INC.

6.1.1. Operating business segments
6.1.2. Business performance
6.1.3. Key strategic moves and developments

6.2. BAYER AG

6.2.1. Operating business segments
6.2.2. Business performance
6.2.3. Key strategic moves and developments

6.3. PERRIGO COMPANY PLC.

6.3.1. Operating business segments
6.3.2. Business performance
6.3.3. Key strategic moves and developments

6.4. SUN PHARMACEUTICAL INDUSTRIES LTD.

6.4.1. Operating business segments
6.4.2. Business performance
6.4.3. Key strategic moves and developments

6.5. APOTEX INC.

6.5.1. Operating business segments
6.5.2. Business performance
6.5.3. Key strategic moves and developments

6.6. PFIZER INC.

6.6.1. Operating business segments
6.6.2. Business performance
6.6.3. Key strategic moves and developments

6.7. SANDOZ INTERNATIONAL GMBH

6.7.1. Operating business segments
6.7.2. Business performance
6.7.3. Key strategic moves and developments

6.8. MYLAN N.V.

6.8.1. Operating business segments
6.8.2. Business performance
6.8.3. Key strategic moves and developments

6.9. SL PHARM LABS

6.9.1. Operating business segments
6.9.2. Business performance
6.9.3. Key strategic moves and developments

6.10. CADILA PHARMACEUTICALS

6.10.1. Operating business segments
6.10.2. Business performance
6.10.3. Key strategic moves and developments